Estrogen replacement therapy is known to reduce the incidence of cardiovascular disease in postmenopausal women, and its beneficial effect is thought to be mediated in part by the favorable changes in serum lipoprotein levels. However, the long-term e...
Estrogen replacement therapy is known to reduce the incidence of cardiovascular disease in postmenopausal women, and its beneficial effect is thought to be mediated in part by the favorable changes in serum lipoprotein levels. However, the long-term effects on serum lipoprotein levels of setrogens in low doses currently used have not been precisely evaluated in Korean postmenopausal women. We conducted the randomized 1-year trials of estrogens in postmenopausal women to evaluate the long-term effects of oral estrogen (Premarin at the dose of 0.625 mg per day, 32 patients) and transdermal estrogen (Estraderm TTS at the dose of 50 micro g per day, 30 patients) on serum lipoprotein levels. Serum total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol levels in fasting state were measured in all subjects at baseline and every 3 month during treatment for 12 months. The values during treatment levels were compared with that of baseline levels. The conjugated estrogen (Premarin) and trasdermal estrogen increased the serm HDL cholesterol levels throughout the study period. The increase of HDL cholesterol in the Estraderm group was somewhat less than that in the Premarin group at 3 months of treatment, but the thereafter no difference was observed between two groups. Serum LDL cholesterol levels did not change significantly in both groups. And serum total cholesterol levels also did not change significantly in both groups except at 12 months of treatment in the Premarine group. Significant increases in serum triglyceride levels were noted in the Premarin group from 6 months of treatment, but not in the Estraderm group. These data suggest that estrogens in low doses, administered by either oral or percutaneous route, maintain the long-term favorable effects on serum lipoprotein levels in postmenopausal women.